Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic enteric bacteria are a diverse group of bacteria that colonize the intestinal tract and cause disease through various mechanisms, including toxin production, invasion of host cells, and disruption of normal gut flora. They are major causes of gastroenteritis, foodborne illnesses, and nosocomial infections, posing significant risks, especially for vulnerable populations.
Antibiotics target various bacterial processes, including cell wall synthesis, protein synthesis, DNA replication, and metabolic pathways. Probiotics aim to restore healthy gut flora. FMT introduces a healthy microbial community to outcompete pathogenic bacteria.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic Enteric Bacteria.